Innoviva Inc - Company Profile
Powered by 
All the data and insights you need on Innoviva Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Innoviva Inc Strategy Report
- Understand Innoviva Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Innoviva Inc (Innoviva) is a company with a portfolio of royalties. It partners with companies that advance innovative therapies for improving patient care and building long-lasting value. Its operations primarily focus on royalty management. The company has partnership agreements with GSK for commercialization and development of respiratory products. Its current portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK) for various respiratory disorders. The company's R&D also focuses on developing innovative formulations for the treatment of respiratory disorders. It receives royalty payments on the sale of these partnered products to clients as per the terms of its agreements with GSK. Innoviva is headquartered in Brisbane, California, the US.
Headquarters
United States of America
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, California, 94010
Website
www.inva.com
Telephone
1 650 2389600
No of Employees
101
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
INVA (NASD)
Revenue (2022)
$331.3M
-15.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-19.5%
(2022 vs 2021)
Market Cap*
$945.3M
Net Profit Margin (2022)
XYZ
-4.8%
(2022 vs 2021)
* As of and is in US$
Innoviva Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Royalty Portfolio: |
| Anoro Ellipta |
| Relvar/Breo |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In May, Innoviva Specialty Therapeutics announced that the U.S. Food and Drug Administration (FDA) approved XACDURO, co-packaged for intravenous use in patients 18 years of age and older to treat patients with bacterial pneumonia and ventilator-associated bacterial pneumonia. |
| 2023 | New Products/Services | In May, the company introduced Innoviva Specialty Therapeutics. |
| 2023 | Contracts/Agreements | In January, Innoviva Strategic Opportunities LLC closed a secured convertible credit agreement with Armata Pharmaceuticals, Inc. |
Competitor Comparison
| Key Parameters | Innoviva Inc | Merck & Co Inc | AstraZeneca Plc | GSK plc | Viatris Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | United Kingdom | United States of America |
| City | Burlingame | Kenilworth | Cambridge | Brentford | Canonsburg |
| State/Province | California | New Jersey | England | England | Pennsylvania |
| No. of Employees | 101 | 69,000 | 89,900 | 69,400 | 37,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pavel Raifeld | Chief Executive Officer | Senior Management | 2020 | 39 |
| Steve Basso | Chief Financial Officer | Senior Management | - | - |
| Marianne Zhen | Chief Accounting Officer | Senior Management | 2018 | 54 |
| Matt Ronsheim, Ph.D | Chief Technology Officer | Senior Management | - | - |
| Christine Coyne | Chief Commercial Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward